When measured with the Advantage system, calcitonin
concentrations are higher in young infants than in adults; similar results have already been obtained with an isotopic method, which showed that concentrations are particularly high during the first week of life (4, 5), in low-birth-weight children (3), and in premature infants (6,8).
also decreased bone-specific alkaline phosphatase levels, compared with placebo, but to a lesser degree than did alendronate.
2] did not include data from more recent clinical trials of oral calcitonins
, including Tarsa's oral calcitonin
prescriptions, down from the 48% August market share.
In October 2012, Tarsa presented data at the American Society for Bone and Mineral Research 2012 Annual Meeting assessing whether there was any sign of increased cancer risk in the 694 women who participated in the company's two separate year-long trials of its investigational oral calcitonin
for the treatment and prevention of post-menopausal osteoporosis.
The Phase II results reinforce the findings of the Phase III ORACAL trial, which showed that Tarsa's oral calcitonin
demonstrated superiority to both placebo and nasal calcitonin
spray in increasing BMD at the lumbar spine after 48 weeks in postmenopausal women with osteoporosis.
Ashleigh Palmer, Chief Executive Officer, stated, "We are delighted with the positive results from Tarsa's study of oral calcitonin
in postmenopausal women with osteopenia.
Tarsa's oral calcitonin
has generated promising data in Phase II studies and the global Phase III clinical program is now underway.
Study Slated for Presentation at ASBMR 2012 Assesses Whether Tarsa's Oral Calcitonin
Was Associated with Increased Cancer Risk in Two Year-Long Postmenopausal Osteoporosis Trials-
Nighttime Dosing May Increase Therapeutic Benefit of Calcitonin
The patient agreed to a trial of calcitonin
therapy and after three days he reported that the burning pain had decreased significantly and was no longer troublesome.
today announced that Novartis Pharma AG and its license partner Nordic Bioscience a/s (the "Sponsor") have reported the following in connection with their Phase III Study 2302 in osteoarthritis assessing the safety and efficacy of oral calcitonin
in the treatment of osteoarthritis of the knee.